CLINICAL ROLE -
Rheumatoid Arthritis Biosimilar as Effective as Adalimumab
Novel Drug Shows Promise in Rheumatoid Arthritis Treatment
Baricitinib Tops Adalimumab in Rheumatoid Arthritis Trial
Complera by Gilead Sciences, Inc
Complera treats HIV infection in previously untreated adults with a viral load of 100,000 copies/mL or less.
2015: The Year in Oncology Drugs
The second article in a two-part series examines oncology drug approvals and late-breaking FDA actions.
The Best and Worst Consequences of Rising Specialty Drug Costs
Specialty pharmacies could serve as the primary conduit to generate value from at-risk agreements between manufacturers and providers.
USP : Key Changes and Additions to USP
USP may subject pharmacies to both state board and FDA inspections.
Billions of Dollars and More Than a Decade Later, Now What?
The global launch of a new drug requires careful orchestration of sales and marketing support activities—a challenge that can have a large financial impact.
Novartis Corporate Integrity Agreement Provides Outline for Pharma-Contracting Compliance Programs
Industry stakeholders must carefully examine every detail of drug adherence programs to ensure compliance with the Anti-Kickback Statute.
Taking Stock of Compliance Issues Impacting Specialty Pharmacy Arrangements
Unique compliance issues may affect specialty pharmacy distribution plans.
Specialty Pipeline Highlights
Approvals expected for new drugs to treat bladder cancer and advanced ER+ breast canÂcer.
The Value Potential of Biosimilars in the United States
Pharmacists must understand the potential value of biosimilars as a competitive generation of more cost efficient drugs hit the market.
OptiMed Pharmacy Extends Beyond Individualized Patient Care
OptiMed takes a value-driven approach to specialty patient management.
Gene Editing: What is CRISPR and its Specialty Impact?
CRISPR technology may eventually hit the specialty landscape with promising treatments for HIV and cancer.
Specialty Pharmacy: Professional Services or Getting Too Cozy?
Lines must be drawn among specialty pharmacies and manufacturers to ensure professional services do not exceed regulatory parameters.
A Year of Dominance Behind, a Year of Dominance Ahead
